A survey of hepatitis B patients, asymptomatic hepatitis B antigen (HB8Ag) carriers, and control subjects was conducted to determine the relationship between antigenemia and antigen excretion in saliva, urine, and stool. Radioimmunoassay was used to detect HB8Ag. Specificity-confirmed HBeAg was detected Specimen collection. From 5 to 10 ml of saliva and 100 ml of first-morning urine were collected twice weekly from hepatitis and orthopedic patients during their hospital stay. A stool specimen was obtained once a week. Saliva and urine samples were collected in sterile glass jars and stored at -20 C until tested for HB.Ag. In six hepatitis patients, 24-h urine collections were obtained. Blood was drawn from all subjects, and the serum was stored at -20 C. Convalescent samples of serum, urine, and saliva were obtained from all available hepatitis patients 3 months after hospital admission. Reagent strips (BiliLabstix, Ames Co.) were used to detect blood in saliva and urine. Reagent tablets (Hematest, Ames Co.) were used for detecting blood in stool.
nonantigenemic patients, 14 (34%) of 41 carriers, and 0 of 112 controls. HB.Ag was detected in urine only after 100-fold concentration of first-morning specimens. Specificity-confirmed HB8Ag was present in the urine of 7 (16%) of 43 carriers; unconfirmed HB8Ag was found in the urine of 5 (13%) of 38 patients and 5 (5%) of 112 controls. Unconfirmed HB8Ag was found in the urine of 5 (13%) of 38 patients and 5 (5%) of 112 controls. Unconfirmed HB8Ag was detected in concentrated stool specimens from 5 (46%) of 11 patients and 0 of 8 carriers and controls. Longitudinally collected specimens from antigenemic subjects showed no consistent patterns of antigen excretion.
Asymptomatic hepatitis B antigen (HB8Ag) has been detected in serum (15) , urine (2, 14) , stool (3, 8) , seminal fluid (4), and menstrual blood (8) . Since HB.Ag-positive serum has been shown to be capable of transmitting hepatitis B infection by mouth (6) , the presence of HB,Ag in the other substances implies the potential for nonparenteral transmission of hepatitis B virus (HBV). This survey was conducted to determine the relationship between antigenemia and excretion of HB8Ag in saliva, urine, and stool in acute hepatitis cases and asymptomatic antigen carriers.
MATERIALS AND METHODS
Subjects. The Specimen collection. From 5 to 10 ml of saliva and 100 ml of first-morning urine were collected twice weekly from hepatitis and orthopedic patients during their hospital stay. A stool specimen was obtained once a week. Saliva and urine samples were collected in sterile glass jars and stored at -20 C until tested for HB.Ag. In six hepatitis patients, 24-h urine collections were obtained. Blood was drawn from all subjects, and the serum was stored at -20 C. Convalescent samples of serum, urine, and saliva were obtained from all available hepatitis patients 3 months after hospital admission. Reagent strips (BiliLabstix, Ames Co.) were used to detect blood in saliva and urine. Reagent tablets (Hematest, Ames Co.) were used for detecting blood in stool.
Concentration of urine and stool. Because HB8Ag
was not found in any unconcentrated urine samples, first-morning urine specimens (100 ml) were concentrated 100-fold by filtration across PM-30 membranes (Amicon). After the concentration procedure, the supernate as well as a I to 2 ml of eluate of the PM-30 membrane were stored at -20 C until tested for HB8Ag. Urine samples (24 h) were concentrated 250-to 500-fold over a single membrane and processed as above. Stool samples (20 g) were homogenized in 100 ml of tris(hydroxymethyl)aminomethane buffer and then concentrated 100-fold as above. Portions (0.2 ml) of supernatant and eluate were adjusted to pH 2.0 with HCl because preliminary tests (using stool specimens to which HB8Ag-positive serum had been added) showed that this procedure would increase the rate of detection of HB8Ag in stool. Both acid-treated and untreated, concentrated stool samples were tested for HB8Ag.
HB8Ag testing. Portions (0.1 ml) of concentrated urine and stool specimens, and unconcentrated saliva and serum samples, were processed as described for serum by radioimmunoassay (RIA) using the Ausria test kit (7 (1, 5, 13) , RIA-positive sera were tested for specificity by an inhibition test using antibody (anti-HB8) to surface antigen.
RESULTS
The frequency of detection of HB.Ag in saliva from patients, carriers, and controls is shown in Table 1 . There was no apparent trend in rates of positivity of specimens collected at twice weekly intervals from patients. The nonantigenemic hepatitis patient with antigen in his saliva had anti-HB8 in his convalescent serum, indicating HBV infection. The presence of small amounts of blood in the saliva specimens did not appear to influence the rate of detection of HB.Ag, since the proportion of specimens containing blood (60%) was the same in both antigen-positive and antigen-negative specimens.
The results of testing concentrated firstmorning urine specimens for HB.Ag are presented in Table 2 . Eleven (18%) of 63 antigenemic subjects had HB8Ag-positive urine. Because of low counts per minute specificity was confirmed on only 7 (27%) of the 26 positive samples from these subjects. When 24-h urine collections from three randomly selected antigenemic hepatitis patients were concentrated 500-fold, two patients had no detectable antigen in their urine, whereas the third had specificityconfirmed HB.Ag in each of five samples.
The data from asymptomatic carriers were examined for a possible association between Table 4 .
Serum, saliva, and urine specimens were collected from 11 antigenemic and 9 nonantigenemic hepatitis patients 3 22 nm in diameter; as a filamentous structure 22 nm in cross-section; and as the outer surface of the 45-nm Dane particle, which is believed to be the HBV. In serum from patients and carriers, the number of 22-nm particles greatly exceeds the number of Dane particles (i.e., presumably infectious virions). Whether a similar ratio of particles exists in saliva, urine, and stool is unknown but may be important in terms of transmission of HBV. For example, if most of the HB.Ag is in the form of Dane particles, then the substance is more likely to be infectious than if most is in the form of 22-nm particles. Therefore, the full implications of detecting HB.Ag in saliva, urine, or stool are as yet unknown; however, epidemiological studies of close personal contacts of asymptomatic HB.Ag carriers strongly support the concept of nonparenteral transmission of HBV (5, 13).
Although HB.Ag was most frequently found Our findings suggest that when HB.Ag is present in the serum, it may also be in the saliva, urine, and stool. Whether the presence of HB.Ag in these substances will correlate with their infectivity remains to be determined. Until infectivity tests are possible, saliva, urine, and stool from antigenemic persons should be considered infectious.
